<DOC>
	<DOC>NCT00057369</DOC>
	<brief_summary>This is a study to evaluate a new medication dosed once a week in the treatment of bacterial infections in the blood from intravenous catheters (CR-BSI). The primary objective is to evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI relative to a standard of care treatment, vancomycin.</brief_summary>
	<brief_title>Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections</brief_title>
	<detailed_description />
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Dalbavancin</mesh_term>
	<mesh_term>Teicoplanin</mesh_term>
	<criteria>The patient or his/her legally authorized representative has given informed consent by means approved by the investigatorâ€™s IRB/EC; &gt; 18 years of age; Had one or more central venous catheters at the time initial signs of infection were evident; Creatinine clearance &lt;50 mL/min; Bilirubin &gt; 2x the upper limit of normal; Treatment with an antibiotic effective against Grampositive bacterial infections for more than 24 hours within 48 hours of study medication initiation, Prolonged antibiotic therapy for CRBSI anticipated (i.e., &gt;2 weeks)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2003</verification_date>
</DOC>